Found: 19
Select item for more details and to access through your institution.
Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 3, p. 1, doi. 10.1093/ofid/ofae007
- By:
- Publication type:
- Article
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 8, p. 1492, doi. 10.1093/cid/ciac949
- By:
- Publication type:
- Article
Corrigendum to: CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.
- Published in:
- Clinical Infectious Diseases, 2021, v. 73, n. 11, p. e3902, doi. 10.1093/cid/ciaa1073
- By:
- Publication type:
- Article
Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa.
- Published in:
- BMC Infectious Diseases, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12879-022-07429-9
- By:
- Publication type:
- Article
Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 12, p. 1, doi. 10.1093/ofid/ofac587
- By:
- Publication type:
- Article
Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. N.PAG, doi. 10.1038/s41467-020-19801-x
- By:
- Publication type:
- Article
Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa.
- Published in:
- Journal of the International AIDS Society, 2024, v. 27, n. 7, p. 1, doi. 10.1002/jia2.26268
- By:
- Publication type:
- Article
CD4 cell count variability with repeat testing in South Africa: Should reporting include both absolute counts and ranges of plausible values?
- Published in:
- 2018
- By:
- Publication type:
- journal article
Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa.
- Published in:
- British Journal of Clinical Pharmacology, 2024, v. 90, n. 5, p. 1247, doi. 10.1111/bcp.16009
- By:
- Publication type:
- Article
Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 3, p. 883, doi. 10.1111/bcp.15177
- By:
- Publication type:
- Article
Slow and Steady But Not Related to HIV Stigma: Physical Activity in South Africans Living with HIV and Chronic Pain.
- Published in:
- AIDS & Behavior, 2023, v. 27, n. 6, p. 1950, doi. 10.1007/s10461-022-03928-7
- By:
- Publication type:
- Article
WEIGHT LOSS AND METABOLIC CHANGES AFTER SWITCHING FROM TAF/FTC/ DTG TO TDF/3TC/DTG.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 264
- By:
- Publication type:
- Article
High individual pain variability in people living with HIV: A graphical analysis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2022, v. 77, n. 11, p. 3110, doi. 10.1093/jac/dkac290
- By:
- Publication type:
- Article
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2022, v. 77, n. 10, p. 2706, doi. 10.1093/jac/dkac266
- By:
- Publication type:
- Article
Risks of metabolic syndrome in the ADVANCE and NAMSAL trials.
- Published in:
- Frontiers in Reproductive Health, 2023, v. 5, p. 1, doi. 10.3389/frph.2023.1133556
- By:
- Publication type:
- Article